{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T04:08:42Z","timestamp":1769918922940,"version":"3.49.0"},"reference-count":67,"publisher":"Japanese Circulation Society","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ J"],"published-print":{"date-parts":[[2014]]},"DOI":"10.1253\/circj.cj-14-0592","type":"journal-article","created":{"date-parts":[[2014,7,8]],"date-time":"2014-07-08T23:28:26Z","timestamp":1404862106000},"page":"1816-1823","source":"Crossref","is-referenced-by-count":25,"title":["Novel Diuretic Strategies for the Treatment of Heart Failure in Japan"],"prefix":"10.1253","volume":"78","author":[{"given":"Kaoru","family":"Dohi","sequence":"first","affiliation":[{"name":"Department of Cardiology and Nephrology, Mie University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Nephrology, Mie University Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. YancyCW,JessupM,BozkurtB,ButlerJ,CaseyDEJr,DraznerMH, et al.2013 ACCF\/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation\/American Heart Association task force on practice guidelines.<i>J Am Coll Cardiol<\/i>2013;62:e147\u2013e239, doi:10.1016\/j.jacc.2013.05.019.","DOI":"10.1016\/j.jacc.2013.05.019"},{"key":"2","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-66-0068"},{"key":"3","unstructured":"3. MaiselAS,PeacockWF,McMullinN,JessieR,FonarowGC,WynneJ, et al.Timing of immunoreactive b-type natriuretic peptide levels and treatment delay in acute decompensated heart failure: An ADHERE (Acute Decompensated Heart Failure National Registry) analysis.<i>J Am Coll Cardiol<\/i>2008;52:534\u2013540."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. PeacockWF4th,FonarowGC,EmermanCL,MillsRM,WynneJ.Impact of early initiation of intravenous therapy for acute decompensated heart failure on outcomes in ADHERE.<i>Cardiology<\/i>2007;107:44\u201351.","DOI":"10.1159\/000093612"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. WalmaEP,HoesAW,van DoorenC,PrinsA,van der DoesE.Withdrawal of long-term diuretic medication in elderly patients: A double blind randomised trial.<i>BMJ<\/i>1997;315:464\u2013468.","DOI":"10.1136\/bmj.315.7106.464"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. FelkerGM.Loop diuretics in heart failure.<i>Heart Fail Rev<\/i>2012;17:305\u2013311.","DOI":"10.1007\/s10741-011-9245-3"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. FelkerGM,O\u2019ConnorCM,BraunwaldE.Loop diuretics in acute decompensated heart failure: Necessary? Evil? A necessary evil?<i>Circ Heart Fail<\/i>2009;2:56\u201362.","DOI":"10.1161\/CIRCHEARTFAILURE.108.821785"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. KinugawaK,SatoN,InomataT,ShimakawaT,IwatakeN,MizuguchiK.Efficacy and safety of tolvaptan in heart failure patients with volume overload.<i>Circ J<\/i>2014;78:844\u2013852.","DOI":"10.1253\/circj.CJ-66-0093"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. WatanabeK,DohiK,SugimotoT,YamadaT,SatoY,IchikawaK, et al.Short-term effects of low-dose tolvaptan on hemodynamic parameters in patients with chronic heart failure.<i>J Cardiol<\/i>2012;60:462\u2013469.","DOI":"10.1016\/j.jjcc.2012.09.002"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. MatsueY,SuzukiM,SeyaM,IwatsukaR,MizukamiA,NagahoriW, et al.Tolvaptan reduces the risk of worsening renal function in patients with acute decompensated heart failure in high-risk population.<i>J Cardiol<\/i>2013;61:169\u2013174.","DOI":"10.1016\/j.jjcc.2012.08.020"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. ShirakabeA,HataN,YamamotoM,KobayashiN,ShinadaT,TomitaK, et al.Immediate administration of tolvaptan prevents the exacerbation of acute kidney injury and improves the mid-term prognosis of patients with severely decompensated acute heart failure.<i>Circ J<\/i>2014;78:911\u2013921.","DOI":"10.1253\/circj.CJ-13-1255"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. ImamuraT,KinugawaK,ShigaT,KatoN,MuraokaH,MinatsukiS, et al.Novel criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patients: Association between non-responders and chronic kidney disease.<i>Circ J<\/i>2013;77:397\u2013404.","DOI":"10.1253\/circj.CJ-12-0971"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. SuzukiS,YoshihisaA,YamakiT,SugimotoK,KuniiH,NakazatoK, et al.Acute heart failure volume control multicenter randomized (AVCMA) trial: Comparison of tolvaptan and carperitide.<i>J Clin Pharmacol<\/i>2013;53:1277\u20131285.","DOI":"10.1002\/jcph.197"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. NomuraF,KurobeN,MoriY,HikitaA,KawaiM,SuwaM, et al.Multicenter prospective investigation on efficacy and safety of carperitide as a first-line drug for acute heart failure syndrome with preserved blood pressure: COMPASS: Carperitide effects observed through monitoring dyspnea in acute decompensated heart failure study.<i>Circ J<\/i>2008;72:1777\u20131786.","DOI":"10.1253\/circj.CJ-07-0760"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. HataN,SeinoY,TsutamotoT,HiramitsuS,KanekoN,YoshikawaT, et al.Effects of carperitide on the long-term prognosis of patients with acute decompensated chronic heart failure: The PROTECT multicenter randomized controlled study.<i>Circ J<\/i>2008;72:1787\u20131793.","DOI":"10.1253\/circj.CJ-08-0130"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. KajimotoK,SatoN,KeidaT,MizunoM,SakataY,AsaiK, et al.Association between length of stay, frequency of in-hospital death, and causes of death in Japanese patients with acute heart failure syndromes.<i>Int J Cardiol<\/i>2013;168:554\u2013556.","DOI":"10.1016\/j.ijcard.2013.01.187"},{"key":"17","unstructured":"17. FormanDE,ButlerJ,WangY,AbrahamWT,O\u2019ConnorCM,GottliebSS, et al.Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure.<i>J Am Coll Cardiol<\/i>2004;43:61\u201367."},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. ButlerJ,FormanDE,AbrahamWT,GottliebSS,LohE,MassieBM, et al.Relationship between heart failure treatment and development of worsening renal function among hospitalized patients.<i>Am Heart J<\/i>2004;147:331\u2013338.","DOI":"10.1016\/S0002-8703(03)00708-7"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. CowieMR,KomajdaM,Murray-ThomasT,UnderwoodJ,TichoB.Prevalence and impact of worsening renal function in patients hospitalized with decompensated heart failure: Results of the Prospective Outcomes Study in Heart failure (POSH).<i>Eur Heart J<\/i>2006;27:1216\u20131222.","DOI":"10.1093\/eurheartj\/ehi859"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. DammanK,NavisG,VoorsAA,AsselbergsFW,SmildeTD,ClelandJG, et al.Worsening renal function and prognosis in heart failure: Systematic review and meta-analysis.<i>J Cardiac Fail<\/i>2007;13:599\u2013608.","DOI":"10.1016\/j.cardfail.2007.04.008"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. MetraM,DavisonB,BettariL,SunH,EdwardsC,LazzariniV, et al.Is worsening renal function an ominous prognostic sign in patients with acute heart failure? The role of congestion and its interaction with renal function.<i>Circ Heart Fail<\/i>2012;5:54\u201362.","DOI":"10.1161\/CIRCHEARTFAILURE.111.963413"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. DohiK,ItoM.Immediate and short-term use of tolvaptan for acute decompensated heart failure.<i>Circ J<\/i>2014;78:829\u2013831.","DOI":"10.1253\/circj.CJ-14-0189"},{"key":"23","unstructured":"23. CostanzoMR,GuglinME,SaltzbergMT,JessupML,BartBA,TeerlinkJR, et al.Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure.<i>J Am Coll Cardiol<\/i>2007;49:675\u2013683."},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. GheorghiadeM,PangPS,AmbrosyAP,LanG,SchmidtP,FilippatosG, et al.A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: Analysis from the EVEREST trial.<i>Heart Fail Rev<\/i>2012;17:485\u2013509.","DOI":"10.1007\/s10741-011-9280-0"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. AdamsKFJr,FonarowGC,EmermanCL,LeJemtelTH,CostanzoMR,AbrahamWT, et al.Characteristics and outcomes of patients hospitalized for heart failure in the united states: Rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE).<i>Am Heart J<\/i>2005;149:209\u2013216.","DOI":"10.1016\/j.ahj.2004.08.005"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. FonarowGC,HeywoodJT,HeidenreichPA,LopatinM,YancyCW.Temporal trends in clinical characteristics, treatments, and outcomes for heart failure hospitalizations, 2002 to 2004: Findings from Acute Decompensated Heart Failure National Registry (ADHERE).<i>Am Heart J<\/i>2007;153:1021\u20131028.","DOI":"10.1016\/j.ahj.2007.03.012"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. HamaguchiS,KinugawaS,Tsuchihashi-MakayaM,GotoD,YamadaS,YokoshikiH, et al.Characteristics, management, and outcomes for patients during hospitalization due to worsening heart failure-a report from the Japanese Cardiac Registry of heart failure in Cardiology (JCARE-CARD).<i>J Cardiol<\/i>2013;62:95\u2013101.","DOI":"10.1016\/j.jjcc.2013.03.009"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. AhmedA,HusainA,LoveTE,GambassiG,Dell\u2019ItaliaLJ,FrancisGS, et al.Heart failure, chronic diuretic use, and increase in mortality and hospitalization: An observational study using propensity score methods.<i>Eur Heart J<\/i>2006;27:1431\u20131439.","DOI":"10.1093\/eurheartj\/ehi890"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. HasselbladV,Gattis StoughW,ShahMR,LokhnyginaY,O\u2019ConnorCM,CaliffRM, et al.Relation between dose of loop diuretics and outcomes in a heart failure population: Results of the ESCAPE trial.<i>Eur J Heart Fail<\/i>2007;9:1064\u20131069.","DOI":"10.1016\/j.ejheart.2007.07.011"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. EshaghianS,HorwichTB,FonarowGC.Relation of loop diuretic dose to mortality in advanced heart failure.<i>Am J Cardiol<\/i>2006;97:1759\u20131764.","DOI":"10.1016\/j.amjcard.2005.12.072"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. NeubergGW,MillerAB,O\u2019ConnorCM,BelkinRN,CarsonPE,CroppAB, et al.Diuretic resistance predicts mortality in patients with advanced heart failure.<i>Am Heart J<\/i>2002;144:31\u201338.","DOI":"10.1067\/mhj.2002.123144"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. MielniczukLM,TsangSW,DesaiAS,NohriaA,LewisEF,FangJC, et al.The association between high-dose diuretics and clinical stability in ambulatory chronic heart failure patients.<i>J Card Fail<\/i>2008;14:388\u2013393.","DOI":"10.1016\/j.cardfail.2008.01.015"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. FrancisGS,BenedictC,JohnstoneDE,KirlinPC,NicklasJ,LiangCS, et al.Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: A substudy of the studies of left ventricular dysfunction (SOLVD).<i>Circulation<\/i>1990;82:1724\u20131729.","DOI":"10.1161\/01.CIR.82.5.1724"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. FrancisGS,SiegelRM,GoldsmithSR,OlivariMT,LevineTB,CohnJN.Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure: activation of the neurohumoral axis.<i>Ann Intern Med<\/i>1985;103:1\u20136.","DOI":"10.7326\/0003-4819-103-1-1"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. BaylissJ,ThomasL,Poole-WilsonP.Acute hemodynamic and neuroendocrine effects of dopexamine, a new vasodilator for the treatment of heart failure: Comparison with dobutamine, captopril, and nitrate.<i>J Cardiovasc Pharmacol<\/i>1987;9:551\u2013554.","DOI":"10.1097\/00005344-198705000-00008"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. EllisonDH.Diuretic therapy and resistance in congestive heart failure.<i>Cardiology<\/i>2001;96:132\u2013143.","DOI":"10.1159\/000047397"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. FelkerGM,MentzRJ.Diuretics and ultrafiltration in acute decompensated heart failure.<i>J Am Coll Cardiol<\/i>2012;59:2145\u20132153.","DOI":"10.1016\/j.jacc.2011.10.910"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. TestaniJM,BriscoMA,TurnerJM,SpatzES,BellumkondaL,ParikhCR, et al.Loop diuretic efficiency: A metric of diuretic responsiveness with prognostic importance in acute decompensated heart failure.<i>Circ Heart Fail<\/i>2014;7:261\u2013270.","DOI":"10.1161\/CIRCHEARTFAILURE.113.000895"},{"key":"39","unstructured":"39. FelkerGM,LeeKL,BullDA,RedfieldMM,StevensonLW,GoldsmithSR, et al.Diuretic strategies in patients with acute decompensated heart failure.<i>N Engl J Med<\/i>2011;364:797\u2013805."},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Abdel-QadirHM,TuJV,YunL,AustinPC,NewtonGE,LeeDS.Diuretic dose and long-term outcomes in elderly patients with heart failure after hospitalization.<i>Am Heart J<\/i>2010;160:264\u2013271.e261.","DOI":"10.1016\/j.ahj.2010.05.032"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. N\u00fa\u00f1ezJ,NunezE,MinanaG,BodiV,FonarowGC,Bertomeu-GonzalezV, et al.Differential mortality association of loop diuretic dosage according to blood urea nitrogen and carbohydrate antigen 125 following a hospitalization for acute heart failure.<i>Eur J Heart Fail<\/i>2012;14:974\u2013984.","DOI":"10.1093\/eurjhf\/hfs090"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. MasuyamaT,TsujinoT,OrigasaH,YamamotoK,AkasakaT,HiranoY, et al.Superiority of long-acting to short-acting loop diuretics in the treatment of congestive heart failure.<i>Circ J<\/i>2012;76:833\u2013842.","DOI":"10.1253\/circj.CJ-11-1500"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. HaradaK,IzawaH,NishizawaT,HirashikiA,MuraseY,KobayashiM, et al.Beneficial effects of torasemide on systolic wall stress and sympathetic nervous activity in asymptomatic or mildly symptomatic patients with heart failure: Comparison with azosemide.<i>J Cardiovasc Pharmacol<\/i>2009;53:468\u2013473.","DOI":"10.1097\/FJC.0b013e3181a717f7"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. EllisonDH.The physiologic basis of diuretic synergism: Its role in treating diuretic resistance.<i>Ann Intern Med<\/i>1991;114:886\u2013894.","DOI":"10.7326\/0003-4819-114-10-886"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. SicaDA,GehrTW.Diuretic combinations in refractory oedema states: Pharmacokinetic-pharmacodynamic relationships. Clin Pharmacokinet.<i>Clin Pharmacokinet<\/i>1996;30:229\u2013249.","DOI":"10.2165\/00003088-199630030-00004"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. JentzerJC,DeWaldTA,HernandezAF.Combination of loop diuretics with thiazide-type diuretics in heart failure.<i>J Am Coll Cardiol<\/i>2010;56:1527\u20131534.","DOI":"10.1016\/j.jacc.2010.06.034"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. OsterJR,EpsteinM,SmollerS.Combined therapy with thiazide-type and loop diuretic agents for resistant sodium retention.<i>Ann Intern Med<\/i>1983;99:405\u2013406.","DOI":"10.7326\/0003-4819-99-3-405"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. HamaguchiS,KinugawaS,Tsuchihashi-MakayaM,MatsushimaS,SakakibaraM,IshimoriN, et al.Hyponatremia is an independent predictor of adverse clinical outcomes in hospitalized patients due to worsening heart failure.<i>J Cardiol<\/i>2014;63:182\u2013188.","DOI":"10.1016\/j.jjcc.2013.07.012"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. SatoN,GheorghiadeM,KajimotoK,MunakataR,MinamiY,MizunoM, et al.Hyponatremia and in-hospital mortality in patients admitted for heart failure (from the ATTEND registry).<i>Am J Cardiol<\/i>2013;111:1019\u20131025.","DOI":"10.1016\/j.amjcard.2012.12.019"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. BansalS,LindenfeldJ,SchrierRW.Sodium retention in heart failure and cirrhosis: Potential role of natriuretic doses of mineralocorticoid antagonist?<i>Circ Heart Fail<\/i>2009;2:370\u2013376.","DOI":"10.1161\/CIRCHEARTFAILURE.108.821199"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. DohiK,WatanabeK,ItoM.Urine osmolality-guided tolvaptan therapy in decompensated heart failure.<i>Circ J<\/i>2013;77:313\u2013314.","DOI":"10.1253\/circj.CJ-12-1535"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52. UdelsonJE,McGrewFA,FloresE,IbrahimH,KatzS,KoshkarianG, et al.Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction.<i>J Am Coll Cardiol<\/i>2007;49:2151\u20132159.","DOI":"10.1016\/j.jacc.2007.01.091"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53. GheorghiadeM,KonstamMA,BurnettJCJr,GrinfeldL,MaggioniAP,SwedbergK, et al.Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: The EVEREST clinical status trials.<i>JAMA<\/i>2007;297:1332\u20131343.","DOI":"10.1001\/jama.297.12.1332"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54. KonstamMA,GheorghiadeM,BurnettJCJr,GrinfeldL,MaggioniAP,SwedbergK, et al.Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST outcome trial.<i>JAMA<\/i>2007;297:1319\u20131331.","DOI":"10.1001\/jama.297.12.1319"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55. UdelsonJE,BilskerM,HauptmanPJ,SequeiraR,ThomasI,O\u2019BrienT, et al.A multicenter, randomized, double-blind, placebo-controlled study of tolvaptan monotherapy compared to furosemide and the combination of tolvaptan and furosemide in patients with heart failure and systolic dysfunction.<i>J Card Fail<\/i>2011;17:973\u2013981.","DOI":"10.1016\/j.cardfail.2011.08.005"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56. Costello-BoerrigterLC,SmithWB,BoerrigterG,OuyangJ,ZimmerCA,OrlandiC, et al.Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure.<i>Am J Physiol Renal Physiol<\/i>2006;290:F273\u2013F278.","DOI":"10.1152\/ajprenal.00195.2005"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57. MiyazakiT,FujikiH,YamamuraY,NakamuraS,MoriT.Tolvaptan, an orally active vasopressin v(2)-receptor antagonist: Pharmacology and clinical trials.<i>Cardiovasc Drug Rev<\/i>2007;25:1\u201313.","DOI":"10.1111\/j.1527-3466.2007.00001.x"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58. GheorghiadeM,GattisWA,O\u2019ConnorCM,AdamsKFJr,ElkayamU,BarbagelataA, et al.Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: A randomized controlled trial.<i>JAMA<\/i>2004;291:1963\u20131971.","DOI":"10.1001\/jama.291.16.1963"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59. BerlT,Quittnat-PelletierF,VerbalisJG,SchrierRW,BichetDG,OuyangJ, et al.Oral tolvaptan is safe and effective in chronic hyponatremia.<i>J Am Soc Nephrol<\/i>2010;21:705\u2013712.","DOI":"10.1681\/ASN.2009080857"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60. PandeyKN.Guanylyl cyclase\/atrial natriuretic peptide receptor-A: Role in the pathophysiology of cardiovascular regulation.<i>Can J Physiol Pharmacol<\/i>2011;89:557\u2013573.","DOI":"10.1139\/y11-054"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61. MizunoO,OnishiK,DohiK,MotoyasuM,OkinakaT,ItoM, et al.Effects of therapeutic doses of human atrial natriuretic peptide on load and myocardial performance in patients with congestive heart failure.<i>Am J Cardiol<\/i>2001;88:863\u2013866.","DOI":"10.1016\/S0002-9149(01)01893-8"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62. NakajimaK,OnishiK,DohiK,TanabeM,KuritaT,YamanakaT, et al.Effects of human atrial natriuretic peptide on cardiac function and hemodynamics in patients with high plasma bnp levels.<i>Int J Cardiol<\/i>2005;104:332\u2013337.","DOI":"10.1016\/j.ijcard.2004.12.020"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63. NishiK,SatoY,MiyamotoT,TomaM,TaniguchiR,FukuharaR, et al.Intermittent infusions of carperitide or inotropes in out-patients with advanced heart failure.<i>J Cardiol<\/i>2012;59:366\u2013373.","DOI":"10.1016\/j.jjcc.2012.01.008"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64. GheorghiadeM,AbrahamWT,AlbertNM,Gattis StoughW,GreenbergBH,O\u2019ConnorCM, et al.Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: An analysis from the OPTIMIZE-HF registry.<i>Eur Heart J<\/i>2007;28:980\u2013988.","DOI":"10.1093\/eurheartj\/ehl542"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65. SezaiA,HataM,NiinoT,YoshitakeI,UnosawaS,WakuiS, et al.Influence of continuous infusion of low-dose human atrial natriuretic peptide on renal function during cardiac surgery: A randomized controlled study.<i>J Am Coll Cardiol<\/i>2009;54:1058\u20131064.","DOI":"10.1016\/j.jacc.2009.05.047"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66. MorikawaS,SoneT,TsuboiH,MukawaH,MorishimaI,UesugiM, et al.Renal protective effects and the prevention of contrast-induced nephropathy by atrial natriuretic peptide.<i>J Am Coll Cardiol<\/i>2009;53:1040\u20131046.","DOI":"10.1016\/j.jacc.2008.10.061"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67. OtsukaT,SakaiY,OhnoD,MurasawaT,SatoN,TsuruokaS.The effects of tolvaptan on patients with severe chronic kidney disease complicated by congestive heart failure.<i>Clin Exp Nephrol<\/i>2013;17:834\u2013838.","DOI":"10.1007\/s10157-013-0788-6"}],"container-title":["Circulation Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/78\/8\/78_CJ-14-0592\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T04:15:08Z","timestamp":1616645708000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/78\/8\/78_CJ-14-0592\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":67,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1253\/circj.cj-14-0592","relation":{},"ISSN":["1346-9843","1347-4820"],"issn-type":[{"value":"1346-9843","type":"print"},{"value":"1347-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]}}}